

abbvie

August 23, 2019

The Honorable TJ Donovan  
Attorney General  
State of Vermont  
109 State Street  
Montpelier, VT 05609


Sent via e-mail to [AGO.DrugCosts@vermont.gov](mailto:AGO.DrugCosts@vermont.gov)

Dear Attorney General Donovan,

AbbVie is providing notice pursuant to 18 V.S.A. § 4637(b) of the August 20, 2019 market introduction date of a new prescription medicine, RINVOQ™ (upadacitinib), for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. The commercial market Wholesale Acquisition Cost (WAC) exceeds the threshold set for a specialty drug under the Medicare Part D Program.

We will be sending the information required under 18 V.S.A. § 4637(c) within the 30-calendar-day timeline.

Sincerely,

A handwritten signature in black ink, appearing to read "Matthew Williams". The signature is fluid and cursive, with a long horizontal stroke at the end.

Matthew Williams  
Vice President, State Government Affairs